

# Country Level Incidence of Alzheimer Disease and Related Dementias is Associated with Increased Omega6 PUFA Consumption

Timothy H. Ciesielski<sup>a</sup>, Giuseppe Tosto<sup>b</sup>, Razaq O. Durodoye<sup>a</sup>, Farid Rajabali<sup>c</sup>, Rufus O. Akinyemi<sup>d</sup>, Goldie S. Byrd<sup>e</sup>, William S. Bush<sup>a,f</sup>, Brian W. Kunkle<sup>c</sup>, Christiane Reitz, Jeffery M. Vance<sup>c</sup>, Margaret A. Pericak-Vance<sup>d</sup>, Jonathan L. Haines<sup>a,f</sup>, and Scott M. Williams<sup>a,f</sup>

<sup>a</sup> Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, 10900 Euclid Ave. Cleveland, OH 44106

<sup>b</sup> Taub Institute for Research on Alzheimer Disease and the Aging Brain, Department of Neurology, Columbia University College of Physicians and Surgeons, 630 West 168th Street New York, NY 10032

<sup>c</sup> John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine 1501 NW 10th Ave. Biomedical Research Building, Miami, FL 33136

<sup>d</sup> Neuroscience and Ageing Research Unit, Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, P.M.B 5017 G.P.O Ibadan, Oyo State, Nigeria.

<sup>e</sup> Maya Angelou Center for Health Equity, Wake Forest University School of Medicine, 525 Vine Street Suite #150, 1st Floor, Winston-Salem, NC 27101

<sup>f</sup> Cleveland Institute for Computational Biology, Case Western Reserve University, 2-530 Wolstein Research Building, 2103 Cornell Road, Cleveland, OH

## \* Corresponding Author:

Timothy H. Ciesielski Sc.D. M.D. M.P.H  
Research Scientist, Department of Population and Quantitative Health Sciences  
Case Western Reserve University School of Medicine  
2210 Circle Drive, Robbins Building, Office E260, Cleveland, Ohio 44106

31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

**Abstract**

**INTRODUCTION:** Clinical and genetic studies have implicated lipid dysfunction in Alzheimer Disease (AD) pathogenesis. However, lipid consumption at the individual-level does not vary greatly within most cohorts, and multiple lipids are rarely measured in any one study.

**METHODS:** Mean country-level lipid intakes were compared to Age-Standardized Alzheimer-Disease-Incidence-Rates(ASAIR) in 183 countries across all inhabited continents. Penalized spline regression and multivariable-adjusted linear regression, including a lag between intake and incidence, were used to assess the relationships between five lipid intakes and ASAIR. Validation was conducted using longitudinal within-country changes between 1990 and 2019.

**RESULTS:** Omega6 Polyunsaturated-Fatty-Acid(PUFA) intake exhibited a positive linear relationship with ASAIR(multivariable-adjusted model:  $\beta=2.44$ ; 95%CI: 1.70, 3.19;  $p=1.38 \times 10^{-9}$ ). ASAIR also increased with saturated-fat, trans-fat, and dietary-cholesterol up to a threshold. The association between Omega6-PUFA and ASAIR was confirmed using longitudinal intake changes.

**DISCUSSION:** Decreasing Omega6-PUFA consumption on the country-level may have substantial benefits in reducing the country-level burden of AD.

## 52 Introduction

53

54 Convergent evidence from genetics, neuropathology, laboratory experiments, and epidemiology  
55 indicates that lipids play a central role in the development of Alzheimer Disease (AD).<sup>1-9</sup> However, the  
56 relative importance of different lipids remains unclear, and individual-level epidemiologic studies are  
57 often not well suited to address this question. Large cohort studies rarely have precise dietary  
58 information on specific lipid intakes over decades, and even where these data are available, the lipid  
59 intakes among individuals do not typically vary enough within a study population to discern patterns of  
60 association. Additionally, multiple categories of lipids are not usually available in one dataset, so their  
61 relative associations cannot be compared. Lastly, the potential for nonlinear relationships is rarely  
62 considered. These caveats often lead to equivocal conclusions upon meta-analysis.<sup>10</sup> However,  
63 each of these issues is addressable with ecological analyses<sup>11</sup> on the country-level. Mean intake  
64 levels for several lipid categories have now been measured with precision and they vary substantially  
65 among nations.<sup>12,13</sup> The range and density of these data should allow for: 1) resolution of associations  
66 with AD incidence, and 2) the use of free-knot penalized spline regression<sup>14</sup> to assess for nonlinear  
67 relationships. Together these factors provide strong impetus for conducting ecological analyses on  
68 the country-level that can characterize the relationship between large-scale lipid intake variations and  
69 AD.

70

71 Here we obtained country-level data on five lipid intakes<sup>12,13</sup>, and compared them to age-standardized  
72 Alzheimer Disease Incidence rates (ASAIR)<sup>15</sup> using free-knot penalized spline regression and linear  
73 regression. We then attempted to validate our findings using longitudinal analyses that compared  
74 changes in country-level lipid intakes over 30 years to changes in ASAIR. These analyses do not

75 seek to make inferences about individual level intakes and the risk of Alzheimer Disease for  
76 individuals. Thus, the ecological fallacy is not a relevant concern as both the exposure and the  
77 outcome are on the country-level. Country-level dietary data is the most appropriate data for studying  
78 country-level incidence rates and country-level interventions.

## 81 Results

82  
83 The mean ASAIR among the 183 countries was: 91.6 new cases per 100,000 per year with a  
84 standard deviation of 11.7 (Table 1). Mean country-level Omega 6 PUFA, saturated fat, and trans-fat  
85 intakes were 5.1%, 11.6%, and 1.1% of total energy intake, respectively, and the mean intakes for  
86 cholesterol and Omega3 PUFA were 323 and 249 mg/day, respectively.

### 88 Cross-sectional Analyses with a Lag

89 Bivariate (unadjusted) free-knot penalized spline regression analyses revealed a linear relationship  
90 between country-level ASAIR and both Omega6 PUFA and Omega3 PUFA (Figure 1: A and B), but  
91 non-linearity was detected for the remaining three lipids: saturated fat, trans-fat, and cholesterol  
92 intake (Figure 1: C, D, and E). ASAIR increased with saturated fat up to ~10% of total energy intake,  
93 and with trans-fat up to ~1.5% total energy intake. ASAIR also increased with dietary cholesterol  
94 intake up to ~250 mg/day. Below these thresholds the relationships appeared linear, while above  
95 these thresholds data was sparse. Thus, the slopes in the high intake regions of the exposure  
96 distribution could not be estimated with confidence, although the plots generally showed slopes near  
97 zero (Figure 1).

99 A multivariable linear regression model adjusted for all other lipids and country development level  
100 (per capita GNI), revealed a positive association between Omega6 PUFA and ASAIR (Table 2;  $\beta =$   
101 2.44; 95%CI: 1.70, 3.19;  $p=1.38 \times 10^{-9}$ ). For Omega3 PUFA there was a subtle negative trend, but the  
102 relationship was not significant ( $\beta = -0.004$ ; 95%CI: -0.010, 0.001;  $p=1.11 \times 10^{-1}$ ). Because the  
103 remaining lipids were modeled with nonlinear splines, it was not appropriate to estimate a single  
104 slope across the full exposure distribution for these lipids. However, as noted above, the remaining  
105 lipid-ASAIR relationships appeared linear below lipid-specific thresholds. Thus, for the three  
106 remaining lipids, we stratified by that lipid's specific threshold, and reran the multivariable model using  
107 a linear term for that lipid. This allowed us to estimate slopes ( $\beta$ s) within the linear regions of the  
108 relationship. Below the threshold of 10% of total energy intake, we found a significant association  
109 between saturated fat and ASAIR ( $\beta = 2.67$ ; 95%CI: 1.23, 4.11;  $p=5.71 \times 10^{-4}$ ). This relationship was  
110 not evidence above the threshold ( $\beta = 0.04$ ; 95%CI: -0.44, 0.53;  $p=8.62 \times 10^{-1}$ ). Similarly, trans-fat  
111 intake was significantly associated with ASAIR below the threshold of 1.5% total energy ( $\beta = 7.35$ ;  
112 95%CI: 0.79, 13.90;  $p=2.96 \times 10^{-2}$ ), but not above the threshold ( $\beta = 0.70$ ; 95%CI: -1.89, 3.29;  
113  $p=6.03 \times 10^{-1}$ ). Finally, the relationship between cholesterol intake and ASAIR was significant below  
114 the threshold of 250 mg/day ( $\beta = 0.15$ ; 95%CI: 0.07, 0.23;  $p=5.98 \times 10^{-4}$ ), but not above it ( $\beta = 0.02$ ;  
115 95%CI: -0.03, 0.07;  $p=3.61 \times 10^{-1}$ ).

116

### 117 Longitudinal Analyses

118 The longitudinal within-country changes in lipid intakes between 1990 and 2010 were small (Table 3),  
119 but the unadjusted regression model validated the association between Omega6-PUFA and ASAIR  
120 (Table 4;  $\beta = 0.0341$ ; 95%CI: 0.0154, 0.0529;  $p=4.70 \times 10^{-4}$ ). Unadjusted regression models for the  
121 other lipids yielded findings that were generally consistent with the cross-sectional findings, but none  
122 of the associations reached significance (Table 4). The longitudinal relationship between Omega6-

123 PUFA and ASAIR remained significant upon multivariable adjustment (Table 4;  $\beta = 0.0375$ ; 95%CI:  
124 0.0164, 0.0586;  $p=6.50 \times 10^{-4}$ ).

125

126

## 127 **Discussion**

128

129 We observed a multivariable-adjusted positive linear association between mean country-level intake  
130 of Omega6 PUFA in 2010 and ASAIR in 2019. This association was then validated with a second  
131 multivariable adjusted model using longitudinal data. Specifically, we found that the percent change  
132 in the country-level Omega6 intake from 1990 to 2010 was positively associated with the percent  
133 change ASAIR between 1990 and 2019. These findings need further validation and trials to establish  
134 if the relationship is causal. However, the validation of this pattern in longitudinal data is among the  
135 strongest corroborations that can be made in non-experimental data. We adjusted for all other lipids  
136 to reduce the risk of bias. With a sample size of 183 countries, we found strong associations in  
137 discovery and in longitudinal validation. These are exceptionally small p-values for an epidemiologic  
138 study with this sample size. Our findings remain significant even under the most conservative  
139 adjustment for multiple testing (considering both discovery and confirmatory regressions as 18  
140 separate tests the Bonferroni adjusted threshold for  $\alpha=0.05$  would be  $p<2.8 \times 10^{-3}$ )

141

142 The association between Omega6 PUFA and Alzheimer Disease is consistent with prior literature in  
143 individual level human studies and animal experiments<sup>8,16–20</sup>. While other studies have reported an  
144 inverse association between Omega3 PUFA and AD<sup>8,21</sup>, here we only observed a non-significant  
145 trend in this direction. Omega3 and Omega6 PUFA share an endogenous processing pathway<sup>22</sup>  
146 involving fatty acid desaturases (FADS) and elongases of very long chain fatty acids (ELOVL).  
147 Interestingly, the gene clusters that produce these enzymes are both implicated in AD<sup>16,23</sup>. Thus, our

148 findings are consistent with the hypothesis that the inflammatory endpoints of Omega6 processing  
149 (e.g. Arachidonic Acid) are more important than the Omega-3 physiology for increasing the risk of  
150 Alzheimer disease.

151  
152 The magnitude of the initial association with Omega6 ( $\beta = 2.44$ ; 95%CI: 1.70, 3.19;  $p=1.38 \times 10^{-9}$ )  
153 indicates that a one standard deviation decrease (-1.9% as a percent of total daily energy intake)  
154 could reduce ASAIR by 4.6 new cases of Alzheimer disease per 100,000 per year ( $2.44 \times 1.9$ ). For the  
155 US, which reported an ASAIR of 110 new cases per 100,000 in 2019, a 2 standard deviation  
156 decrease in mean Omega6 PUFA intake would amount to 8.4% reduction in new cases annually  
157 ( $[(110 - 9.2) / 110 = 91.6\%$ ). In absolute numbers this translates into ~28,140 fewer new cases each year  
158 ( $8.4 \times [335,000,000 / 100,000]$ ). We did not evaluate Alzheimer Disease prevalence in this study  
159 because prevalence is affected by survival time, which can involve factors that are not relevant to  
160 disease etiology. However, if all other factors were held constant, lower annual incidence could  
161 compound over time to reduce the prevalence and societal burden of Alzheimer Disease.

162  
163 Our findings for saturated fat, trans-fat, and dietary cholesterol are also supported by the literature<sup>2,24-</sup>  
164 <sup>27</sup>, but the patterns were not significant in our longitudinal analyses. This is not surprising given the  
165 small magnitude of the longitudinal changes in lipid intakes that were observed within countries.  
166 Individual level studies, both cross-sectional and longitudinal, generally share the same limitation (i.e.  
167 small range of exposure). The results from our free-knot penalized spline regression models remain  
168 critical for future research as they indicate that nonlinear relationships should be considered in future  
169 inquiries of these lipids. If the relationships reported here are validated in subsequent work, then  
170 reductions in saturated fat, trans-fat, and dietary cholesterol may further reduce country-level ASAIR.  
171 For countries below the saturated fat threshold of 10% of total daily energy intake, a two standard  
172 deviation decrease in saturated fat intake would correspond to a reduction in ASAIR by 24.0 new

173 cases of Alzheimer Disease per 100,000 per year (2.67\*9.0). Similar calculations for trans-fat  
174 (7.35\*1.4) and dietary cholesterol (0.15\*110) would predict 10.3 and 16.5 fewer new cases per  
175 100,000 per year, respectively. In 2019 the US had a mean saturated fat intake of 11.8% of total  
176 daily energy intake, a mean trans-fat intake of 2.8% of total daily energy intake, and a mean dietary  
177 cholesterol of 296 mg/day. A two standard deviation decrease for each of these fats would lower the  
178 US mean intakes below the identified intake thresholds (10% of total daily energy intake for saturated  
179 fat, 1.5% of total daily energy intake for trans-fat, and 250 mg/day for dietary cholesterol). Such a  
180 decrease would result in 19.2 fewer new Alzheimer Disease cases per 100,000 per year for saturated  
181 fat reductions (2.67\*7.2), 0.7 fewer new cases per 100,000 per year for trans-fat reductions  
182 (7.35\*0.1), and 9.6 fewer new cases per 100,000 per year for dietary cholesterol reductions (0.15\*64).  
183 When added to the Omega6 PUFA findings, a two standard deviation decrease in Omega6,  
184 Saturated fat, trans-fat, and dietary cholesterol could potentially yield a net reduction of 38.7 new  
185 cases per 100,000 per year in the US. This would amount to a 35.2% reduction in new cases of  
186 Alzheimer Disease in the US each year. ( $[110-38.7]/110 = 64.8\%$ ). In absolute numbers this  
187 translates into ~129,645 fewer new cases each year in the US ( $38.7*[335,000,000/100,000]$ ). Again,  
188 the saturated fat, trans-fat, and dietary cholesterol findings still need to be corroborated on the  
189 country level, but there is substantial motivation to conduct follow-up studies because of the size of  
190 the putative benefits.

191  
192 There are limitations to our work. First, we note that our country-level analyses depend on the  
193 accurate estimation of mean lipid intakes and ASAIR. These estimates come from peer reviewed  
194 publications and extensive care was made to account for potential biases. Second, we note that we  
195 had limited covariates available for confounding adjustment and this is a common issue in country-  
196 level analyses. Nevertheless, we emphasize that the findings in the longitudinal analyses intrinsically  
197 account for confounding factors that are stable in time. In other words, confounding by genetic and



198 environmental factors that are stable within the time course of the analysis, are controlled for by study  
199 design. Additionally, we adjusted both our cross-sectional and longitudinal analyses for country  
200 development level. This can reduce residual bias from factors that are correlated with country level  
201 economic improvement. Perhaps most importantly, the Omega6 PUFA results were validated in the  
202 longitudinal models despite limited power (and the other findings revealed supportive trends). A third  
203 limitation is that the time lags do not perfectly align between the discovery and validation analyses.  
204 We would have preferred to have access to changes in ASAIR between 1999 and 2019 instead of  
205 1990 to 2019. However, this is a minor point and the expected random error would likely bias toward  
206 the null. Finally, we note that while these findings are very useful for country-level inference and  
207 intervention, they are not directly applicable to individual level inference (the ecological fallacy).  
208 Therefore, although our results are compelling at the country level, the individual level will require  
209 additional study.

210  
211 Overall, these findings may provide an approach for reducing ASAIR through food system  
212 interventions. If trials confirm our findings, then we can hone the prevention strategies that  
213 governments need as populations around the globe get older.<sup>28</sup> Importantly, this work stands on vast  
214 convergent evidence<sup>29</sup> implicating lipid dysfunction in Alzheimer disease etiology.<sup>1-9</sup> It is now  
215 becoming clear that lipid abnormalities are causal factors<sup>30</sup> in Alzheimer disease development, and  
216 though lipids have not always been the center of focus for Alzheimer researchers, the genetics have  
217 been consistently pointing in this direction for over 30 years.<sup>1,7</sup> Perhaps most importantly, if achieved,  
218 diet-based interventions could have large impact on Alzheimer disease incidence. While determining  
219 safe, optimal changes to country level lipid intakes needs some additional study, the benefits might  
220 extend beyond ASAIR, as excess Omega6 PUFA in our food systems is linked to many other serious  
221 and common chronic diseases.<sup>31,32</sup> The potential ASAIR benefits will vary by country, but based on  
222 our estimates for the US, a moderate decrease in Omega6 PUFA intake could reduce ASAIR by 8%.

223 Additional decreases in saturated fat, trans-fat, and dietary cholesterol might yield total ASAIR  
224 reductions of 35%. Our findings are promising as they indicate a rather straightforward path to  
225 reducing AD burden.

## 229 **Online Methods**

230  
231 Previously published reports were used to obtain mean intake for 5 lipids (Omega6 polyunsaturated  
232 fatty acids (Omega6 PUFA), Long Chain Omega3 polyunsaturated fatty acids (Omega3 PUFA),  
233 Saturated fat, Trans-fat, and Dietary Cholesterol)<sup>12,13</sup> and ASAIR<sup>15</sup> for 184 countries. One country,  
234 the Maldives, was eliminated from the analyses as it was an extreme outlier with respect to Omega3  
235 PUFA (>9 standard deviations above the global mean). The lipid estimates were produced by the  
236 Nutrition and Chronic Diseases Expert Group (NutriCoDE) for the 2010 Global Burden of Diseases,  
237 Injuries, and Risk Factors Study, and they used a Bayesian hierarchical imputation model to  
238 harmonize these estimates from diverse source data<sup>12,13,33</sup>. ASAIR estimates were produced by the  
239 GBD Disease and Injury Incidence and Prevalence Collaborators and downloaded from the IHME  
240 Global Health Data Exchange (<http://ghdx.healthdata.org/gbd-results-tool>) on March 20, 2020<sup>15</sup>  
241 Incidence rates in this study are for Alzheimer disease and other dementias (national autopsy  
242 programs are not available for diagnostic confirmation at scale). Age standardization was conducted  
243 to account for country-level differences in population age distributions and age of dementia onset.  
244 Lipid intake data was from 2010 and ASAIR values were from 2019. This 9-year time-lag aligns with  
245 optimal lags estimated for environmental factors in Alzheimer Disease epidemiology.<sup>34</sup> Omega3  
246 PUFA estimates were adjusted to account for endogenous conversion as previously described<sup>35</sup>.

## 248 Cross-sectional Analyses with a Lag

249 To assess the shape of the 5 lipid-ASAIR relationships, we implemented free-knot penalized  
250 regression splines using MGCV in R.<sup>14</sup> The three lipid intakes that demonstrated non-linear  
251 relationships with ASAIR in these bivariate regression spline models were specified in the subsequent  
252 multivariable-adjusted model with spline terms. Limited covariate data was available for confounding  
253 adjustments, but this model was adjusted for all other lipids and country development level based on  
254 per capita Gross National Income (GNI)<sup>36</sup>. The per capita GNI for each country in 2010 was  
255 calculated using the World Bank Atlas method as described in Blencowe et al 2012<sup>36</sup> (0=Low-income  
256 economies, 1=Lower-middle-income, 2=Upper-middle-income and 3=High-income economies).  
257 Since the three nonlinear relationships appeared to be linear on either side of a threshold in the  
258 bivariate spline models, we also used the thresholds to create 2 strata for each of these lipids (strata  
259 within which the lipid-ASAIR relationship appears linear). We then specified linear terms for these  
260 lipids and reran the multivariable-adjusted regression model in the two strata separately (to obtain  $\beta$ s  
261 for the linear regions of the lipid-ASAIR relationship).

## 263 Longitudinal Analyses

264 Finally, we compared the percent change in lipid intakes from 1990 to 2010<sup>12,13</sup> to the percent change  
265 in ASAIR between 1990 and 2019<sup>15</sup> with linear regression. We first assessed unadjusted linear  
266 regression models within the linear regions of the relationship identified in the analyses described  
267 above. Any lipid that yielded significant findings was then evaluated in a multivariable-adjusted model  
268 that was adjusted for all other lipids. To identify distinct associations on opposite sides of the  
269 thresholds for saturated fat, trans-fat, and dietary cholesterol, we tested for interaction with a  
270 dichotomous dummy variable for change-occurred-above-or-below threshold. Finally, we adjusted for  
271 changes in country development level based on per capita GNI. This variable was coded as the  
272 development level change from 1990 to 2010. Development levels were not available for 27

273 countries in 1990, but we were able to obtain substitute baseline values for 24 of these countries by  
274 using development estimates from 1991 or 1992.<sup>37</sup> Thus, only Montenegro, Serbia, and Timor-Leste  
275 were excluded due to missing baseline development data in any of these years. Note that the lipid  
276 intake information is the percent change in the country-level intake between 1990 and 2010, and the  
277 incidence data is percent change in the annual age standardized incidence between 1990 and 2019.  
278 Since these units differ from the prior analyses, these data can be used to corroborate association  
279 directions, but the association magnitudes are not directly comparable. Descriptive statistics were  
280 obtained using SAS 9.4 (Cary, NC) and all other analyses were conducted with R 4.2.1.

281

282

## 283 References

284

- 285 1. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and  
286 the risk of Alzheimer's disease in late onset families. *Science*. 1993;261(5123):921-923.  
287 doi:10.1126/science.8346443
- 288 2. Honda T, Ohara T, Shinohara M, et al. Serum elaidic acid concentration and risk of dementia: The  
289 Hisayama Study. *Neurology*. 2019;93(22):e2053-e2064. doi:10.1212/WNL.0000000000008464
- 290 3. Abdullah L, Evans JE, Emmerich T, et al. APOE  $\epsilon$ 4 specific imbalance of arachidonic acid and  
291 docosahexaenoic acid in serum phospholipids identifies individuals with preclinical Mild Cognitive  
292 Impairment/Alzheimer's Disease. *Aging*. 2017;9(3):964-985. doi:10.18632/aging.101203
- 293 4. Ebright B, Assante I, Poblete RA, et al. Eicosanoid lipidome activation in post-mortem brain  
294 tissues of individuals with APOE4 and Alzheimer's dementia. *Alzheimers Res Ther*.  
295 2022;14(1):152. doi:10.1186/s13195-022-01084-7
- 296 5. Moulton MJ, Barish S, Ralhan I, et al. Neuronal ROS-induced glial lipid droplet formation is altered  
297 by loss of Alzheimer's disease-associated genes. *Proc Natl Acad Sci U S A*. 2021;118(52).  
298 doi:10.1073/pnas.2112095118
- 299 6. Thomas MH, Paris C, Magnien M, et al. Dietary arachidonic acid increases deleterious effects of  
300 amyloid- $\beta$  oligomers on learning abilities and expression of AMPA receptors: putative role of the  
301 ACSL4-cPLA(2) balance. *Alzheimers Res Ther*. 2017;9(1):69. doi:10.1186/s13195-017-0295-1
- 302 7. Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer's  
303 disease identifies new risk loci and implicates A $\beta$ , tau, immunity and lipid processing. *Nat Genet*.  
304 2019;51(3):414-430. doi:10.1038/s41588-019-0358-2
- 305 8. Chew H, Solomon VA, Fonteh AN. Involvement of Lipids in Alzheimer's Disease Pathology and  
306 Potential Therapies. *Front Physiol*. 2020;11:598. doi:10.3389/fphys.2020.00598
- 307 9. Haney MS, Pálovics R, Munson CN, et al. APOE4/4 is linked to damaging lipid droplets in  
308 Alzheimer's disease microglia. *Nature*. Published online March 13, 2024. doi:10.1038/s41586-  
309 024-07185-7
- 310 10. Nwaru BI, Dierkes J, Ramel A, et al. Quality of dietary fat and risk of Alzheimer's disease and  
311 dementia in adults aged  $\geq$ 50 years: a systematic review. *Food Nutr Res*. 2022;66.  
312 doi:10.29219/fnr.v66.8629
- 313 11. Pearce N. The ecological fallacy strikes back. *J Epidemiol Community Health*. 2000;54(5):326-  
314 327.
- 315 12. Micha R, Khatibzadeh S, Shi P, et al. Global, regional, and national consumption levels of dietary  
316 fats and oils in 1990 and 2010: a systematic analysis including 266 country-specific nutrition  
317 surveys. *BMJ*. 2014;348:g2272. doi:10.1136/bmj.g2272

- 318 13. Global, regional, and national consumption levels of dietary fats and oils in 1990 and 2010: a  
319 systematic analysis including 266 country-specific nutrition surveys. *BMJ*. 2015;350:h1702.  
320 doi:10.1136/bmj.h1702
- 321 14. Wood SN. Package 'mgcv' : GAMs with GCV/AIC/REML smoothness estimation and GAMMs by  
322 PQL. Published November 30, 2010. Accessed November 30, 2010. [https://cran.r-](https://cran.r-project.org/web/packages/mgcv/mgcv.pdf)  
323 [project.org/web/packages/mgcv/mgcv.pdf](https://cran.r-project.org/web/packages/mgcv/mgcv.pdf) accessed 11/30/2010
- 324 15. Li X, Feng X, Sun X, Hou N, Han F, Liu Y. Global, regional, and national burden of Alzheimer's  
325 disease and other dementias, 1990-2019. *Front Aging Neurosci*. 2022;14:937486.  
326 doi:10.3389/fnagi.2022.937486
- 327 16. Hammouda S, Ghzaïel I, Khamlaoui W, et al. Genetic variants in FADS1 and ELOVL2 increase  
328 level of arachidonic acid and the risk of Alzheimer's disease in the Tunisian population.  
329 *Prostaglandins Leukot Essent Fatty Acids*. 2020;160:102159. doi:10.1016/j.plefa.2020.102159
- 330 17. Sanchez-Mejia RO, Mucke L. Phospholipase A2 and arachidonic acid in Alzheimer's disease.  
331 *Biochim Biophys Acta*. 2010;1801(8):784-790. doi:10.1016/j.bbalip.2010.05.013
- 332 18. Sanchez-Mejia RO, Newman JW, Toh S, et al. Phospholipase A2 reduction ameliorates cognitive  
333 deficits in a mouse model of Alzheimer's disease. *Nat Neurosci*. 2008;11(11):1311-1318.  
334 doi:10.1038/nn.2213
- 335 19. Thomas MH, Pelleieux S, Vitale N, Olivier JL. Dietary arachidonic acid as a risk factor for age-  
336 associated neurodegenerative diseases: Potential mechanisms. *Biochimie*. 2016;130:168-177.  
337 doi:10.1016/j.biochi.2016.07.013
- 338 20. Goozee K, Chatterjee P, James I, et al. Alterations in erythrocyte fatty acid composition in  
339 preclinical Alzheimer's disease. *Sci Rep*. 2017;7(1):676. doi:10.1038/s41598-017-00751-2
- 340 21. Hosseini M, Poljak A, Braidy N, Crawford J, Sachdev P. Blood fatty acids in Alzheimer's disease  
341 and mild cognitive impairment: A meta-analysis and systematic review. *Ageing Res Rev*.  
342 2020;60:101043. doi:10.1016/j.arr.2020.101043
- 343 22. Zhang JY, Kothapalli KS, Brenna JT. Desaturase and elongase-limiting endogenous long-chain  
344 polyunsaturated fatty acid biosynthesis. *Curr Opin Clin Nutr Metab Care*. 2016;19(2):103-110.  
345 doi:10.1097/mco.0000000000000254
- 346 23. Peña-Bautista C, Álvarez-Sánchez L, Cañada-Martínez AJ, Baquero M, Cháfer-Pericás C.  
347 Epigenomics and Lipidomics Integration in Alzheimer Disease: Pathways Involved in Early  
348 Stages. *Biomedicines*. 2021;9(12). doi:10.3390/biomedicines9121812
- 349 24. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and the risk  
350 of incident dementia in the Rotterdam Study. *Ann Neurol*. 1997;42(5):776-782.  
351 doi:10.1002/ana.410420514
- 352 25. Grant WB, Blake SM. Diet's Role in Modifying Risk of Alzheimer's Disease: History and Present  
353 Understanding. *J Alzheimers Dis JAD*. 2023;96(4):1353-1382. doi:10.3233/JAD-230418

- 354 26. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased  
355 risk of Alzheimer's and vascular dementia three decades later. *Dement Geriatr Cogn Disord*.  
356 2009;28(1):75-80. doi:10.1159/000231980
- 357 27. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS. Dietary fat intake and 6-year  
358 cognitive change in an older biracial community population. *Neurology*. 2004;62(9):1573-1579.  
359 doi:10.1212/01.wnl.0000123250.82849.b6
- 360 28. Feigin VL, Vos T, Nichols E, et al. The global burden of neurological disorders: translating  
361 evidence into policy. *Lancet Neurol*. 2020;19(3):255-265. doi:10.1016/S1474-4422(19)30411-9
- 362 29. Ciesielski TH, Pendergrass SA, White MJ, et al. Diverse convergent evidence in the genetic  
363 analysis of complex disease: coordinating omic, informatic, and experimental evidence to better  
364 identify and validate risk factors. *BioData Min*. 2014;7:10. doi:10.1186/1756-0381-7-10
- 365 30. Rothman KJ. Causes. *Am J Epidemiol*. 1976;104(6):587-592.  
366 doi:10.1093/oxfordjournals.aje.a112335
- 367 31. Patterson E, Wall R, Fitzgerald GF, Ross RP, Stanton C. Health implications of high dietary  
368 omega-6 polyunsaturated Fatty acids. *J Nutr Metab*. 2012;2012:539426.  
369 doi:10.1155/2012/539426
- 370 32. Mariamenatu AH, Abdu EM. Overconsumption of Omega-6 Polyunsaturated Fatty Acids (PUFAs)  
371 versus Deficiency of Omega-3 PUFAs in Modern-Day Diets: The Disturbing Factor for Their  
372 "Balanced Antagonistic Metabolic Functions" in the Human Body. *J Lipids*. 2021;2021:8848161.  
373 doi:10.1155/2021/8848161
- 374 33. Micha R, Kalantarian S, Wirojratana P, et al. Estimating the global and regional burden of  
375 suboptimal nutrition on chronic disease: methods and inputs to the analysis. *Eur J Clin Nutr*.  
376 2012;66(1):119-129. doi:10.1038/ejcn.2011.147
- 377 34. Mork D, Braun D, Zanobetti A. Time-lagged relationships between a decade of air pollution  
378 exposure and first hospitalization with Alzheimer's disease and related dementias. *Environ Int*.  
379 2023;171:107694. doi:10.1016/j.envint.2022.107694
- 380 35. Ciesielski TH, Williams SM. Low Omega-3 intake is associated with high rates of depression and  
381 preterm birth on the country level. *Sci Rep*. 2020;10(1):19749. doi:10.1038/s41598-020-76552-x
- 382 36. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of  
383 preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a  
384 systematic analysis and implications. *Lancet*. 2012;379(9832):2162-2172. doi:10.1016/s0140-  
385 6736(12)60820-4
- 386 37. Hamadehc N, Van Rompaey C, Metrea E. World Bank Group country classifications by income  
387 level. Accessed March 12, 2024. [https://blogs.worldbank.org/opendata/new-world-bank-group-  
388 country-classifications-income-level-fy24](https://blogs.worldbank.org/opendata/new-world-bank-group-country-classifications-income-level-fy24)

389

390

391 **Acknowledgements**

392 The authors would like to thank the many people who contributed to the country-level estimates that  
393 were used in these analyses.

394

395 **Conflicts**

396 None

397

398 **Funding Sources**

399 RD was supported by a National Institutes of Health F grant (F30AG082434). The other authors were  
400 supported by the National Institute on Aging (U19 AG074865), which was awarded to GT, FR, ROA,  
401 GSB, WSB, BWK, CR, JMV, MPV, JLH, and SMW. The funding source had no role in the collection,  
402 analysis, interpretation of data, writing of the report, or submission decision.

403

404 **Consent statement**

405 NA – This analysis used country-level data from previously published papers.

406

407 **Key Words**

408 Alzheimer's disease, dementia, lipids, epidemiology, prevention, diet, population health

409

410

411

412

413



414 **Table 1: Descriptive statistics for the 183 countries**

415

	Mean	Standard Deviation	Median	25th Percentile	75th Percentile	Min	Max
<b>Outcome Variable</b>							
<b>Age Standardized Alzheimer Disease Incidence (ASAIR)<sup>a</sup> (new cases annually per 100,000)</b>	91.6	11.7	90.0	80.0	100.0	60.0	110.0
<b>Exposure Variables</b>							
<b>Omega 6 PUFA<sup>b</sup> (% of total daily energy intake)</b>	5.1	1.9	4.9	3.7	6.3	1.2	12.5
<b>Long Chain Omega3 PUFA<sup>b</sup> (mg/day)</b>	323	273	261	153	403	35	2011
<b>Saturated Fat<sup>b</sup> (% of total daily energy intake)</b>	11.6	4.5	11.0	8.8	13.7	2.3	27.5
<b>Trans-fat<sup>b</sup> (% of total daily energy intake)</b>	1.1	0.7	1.0	0.8	1.2	0.2	6.5
<b>Dietary Cholesterol<sup>b</sup> (mg/day)</b>	249	55	247	209	286	97	439
<b>Gross National Income<sup>c</sup></b>	1.6	1.1	2	1	3	0	3

416 <sup>a</sup> ASAIR estimates were obtained from Li et al 2022.<sup>15</sup> They were produced by the *GBD Disease and Injury*  
417 *Incidence and Prevalence Collaborators* and downloaded from the IHME Global Health Data Exchange  
418 (<http://ghdx.healthdata.org/gbd-results-tool>) on March 20, 2020.

419 <sup>b</sup> Lipid estimates were obtained from Micha et al 2015.<sup>12,13,33</sup> They were produced by the *Nutrition and*  
420 *Chronic Diseases Expert Group (NutriCoDE)* for the 2010 Global Burden of Diseases, Injuries, and Risk Factors  
421 Study, and they used a Bayesian hierarchical imputation model harmonize these estimates from diverse  
422 source data<sup>12,13,33</sup>.

423 <sup>c</sup> The development level (based on per capita GNI) for each country in 2010 was calculated using the World  
424 Bank Atlas method as described in Blencowe et al 2012<sup>36</sup> (0=Low-income economies, 1=Lower-middle-income,  
425 2=Upper-middle-income and 3=High-income economies)

426

427

428

429

430

431

**Table 2: Results from regression models of age standardized Alzheimer Disease incidence on the country-level**

	<b>Change in Age Standardized Alzheimer Disease Incidence associated with a 1 unit increase in country-level lipid (<math>\beta</math>)</b>	<b>95% CI</b>	<b>p value</b>
<b>Omega6 PUFA (% of energy intake) <sup>a</sup></b>	2.44	1.70, 3.19	1.38x10 <sup>-9</sup>
<b>Long Chain Omega3 PUFA (mg/day) <sup>a</sup></b>	-0.004	-0.010, 0.001	1.11x10 <sup>-1</sup>
<b>Gross National Income <sup>a</sup></b>	0.29	-1.34 1.92	7.28x10 <sup>-1</sup>
<b>Saturated Fat (% of energy intake) <sup>b</sup></b>			
Below the threshold of 10	2.67	1.23, 4.11	5.71x10 <sup>-4</sup>
Above the threshold of 10	0.04	-0.44, 0.53	8.62x10 <sup>-1</sup>
<b>Trans-fat (% of energy intake) <sup>c</sup></b>			
Below the threshold of 1.5	7.35	0.79, 13.90	2.96x10 <sup>-2</sup>
Above the threshold of 1.5	0.70	-1.89, 3.29	6.03x10 <sup>-1</sup>
<b>Dietary Cholesterol (mg/day) <sup>d</sup></b>			
Below the threshold of 250	0.15	0.07, 0.23	5.98x10 <sup>-4</sup>
Above the threshold of 250	0.02	-0.03, 0.07	3.61x10 <sup>-1</sup>

<sup>a</sup> Multivariable model with Omega6 PUFA, Long Chain Omega3 PUFA (mg/day) and Gross National Income modeled with linear terms, and Saturated Fat, Dietary Cholesterol, and Trans-fat were modeled with penalized splines.

<sup>b</sup> The same model as in a, but now with a linear term for Saturated Fat, and evaluated in two separate strata (above and below the threshold of 10% Saturated fat by total energy intake)

<sup>c</sup> The same model as in a, but now with a linear term for Trans-fat, and evaluated in two separate strata (above and below the threshold of 1.5% Trans-fat by total energy intake)

<sup>d</sup> The same model as in a, but now with a linear term for Dietary Cholesterol, and evaluated in two separate strata (above and below the threshold of 250 mg/day of Dietary Cholesterol)

449 **Table 3: Longitudinal changes in lipid intakes and age standardized Alzheimer Disease**  
 450 **incidence in the 183 countries**

451

	Mean	Standard Deviation	Median	25th Percentile	75th Percentile	Min	Max
<b>Outcome Variable</b>							
<b>Percent Change in Annual Age Standardized Alzheimer Disease Incidence from 1990 to 2019<sup>a</sup></b>	0.012	0.111	0.020	-0.040	0.070	-0.420	0.580
<b>Exposure Variables</b>							
<b>Percent Change in Omega 6 PUFA from 1990 to 2010<sup>b</sup></b>	0.42	0.83	0.30	-0.10	0.70	-2.00	3.40
<b>Percent Change in Long Chain Omega3 PUFA from 1990 to 2010<sup>b</sup></b>	58	79	41	9	94	-193	400
<b>Percent Change in Saturated Fat from 1990 to 2010<sup>b</sup></b>	0.05	1.32	0.00	-0.60	0.50	-4.40	4.60
<b>Percent Change in Trans-fat from 1990 to 2010<sup>b</sup></b>	0.07	0.21	0.00	0.00	0.10	-0.80	1.50
<b>Percent Change in Dietary Cholesterol from 1990 to 2010<sup>b</sup></b>	3.6	19.9	2.2	-10.3	15.7	-57.0	57.8
<b>Change in Gross National Income from 1990 to 2010<sup>c</sup></b>	0.38	0.60	0	0	1	-1	2

452 <sup>a</sup> ASAIR estimates were obtained from Li et al 2022.<sup>15</sup> They were produced by the *GBD Disease and Injury*  
 453 *Incidence and Prevalence Collaborators* and downloaded from the IHME Global Health Data Exchange  
 454 (<http://ghdx.healthdata.org/gbd-results-tool>) on March 20, 2020.

455 <sup>b</sup> Lipid estimates were obtained from Micha et al 2015.<sup>12,13,33</sup> They were produced by the *Nutrition and*  
 456 *Chronic Diseases Expert Group (NutriCoDE)* for the 2010 Global Burden of Diseases, Injuries, and Risk Factors  
 457 Study, and they used a Bayesian hierarchical imputation model harmonize these estimates from diverse  
 458 source data<sup>12,13,33</sup>.

459 <sup>c</sup> This variable was coded as the country development level change (based on per capita GNI) from 1990 to  
 460 2010. Development levels were not available for 27 countries in 1990, but we were able to obtain substitute  
 461 country development baseline values for 24 of these countries by using an estimate from 1991 or 1992.<sup>37</sup>  
 462 Thus, only Montenegro, Serbia, and Timor-Leste were missing country development level change data.  
 463  
 464

465 **Table 4: Results from linear regression models of percent change in annual age standardized**  
 466 **Alzheimer Disease Incidence from 1990 to 2019**

467

	<b>Percent Change in Annual Age Standardized Alzheimer Disease Incidence from 1990 to 2019 associated with a 1% increase in country-level lipid intake (<math>\beta</math>)</b>	<b>95% CI</b>	<b>p value</b>
<b>Unadjusted Models</b>			
<b>Percent Change in Omega 6 PUFA from 1990 to 2010</b>	$3.41 \times 10^{-02}$	$1.54 \times 10^{-02}$ , $5.29 \times 10^{-02}$	$4.70 \times 10^{-04}$
<b>Percent Change in Long Chain Omega3 PUFA from 1990 to 2010</b>	$9.63 \times 10^{-5}$	$-1.08 \times 10^{-4}$ , $3.01 \times 10^{-4}$	$3.58 \times 10^{-1}$
<b>Percent Change in Saturated Fat from 1990 to 2010</b>			
Below the threshold of 10	$4.38 \times 10^{-3}$	$-1.83 \times 10^{-2}$ , $2.70 \times 10^{-2}$	$7.06 \times 10^{-1}$
Above the threshold of 10	$-2.39 \times 10^{-3}$	$-1.71 \times 10^{-2}$ , $1.23 \times 10^{-2}$	$7.51 \times 10^{-1}$
<b>Percent Change in Trans-fat from 1990 to 2010</b>			
Below the threshold of 1.5	$1.37 \times 10^{-1}$	$-2.43 \times 10^{-2}$ , $2.98 \times 10^{-1}$	$9.82 \times 10^{-2}$
Above the threshold of 1.5	$2.28 \times 10^{-2}$	$-6.33 \times 10^{-2}$ , $1.09 \times 10^{-1}$	$6.08 \times 10^{-1}$
<b>Percent Change in Dietary Cholesterol</b>			
Below the threshold of 250	$9.23 \times 10^{-4}$	$-2.44 \times 10^{-4}$ , $2.09 \times 10^{-3}$	$1.24 \times 10^{-1}$
Above the threshold of 250	$2.14 \times 10^{-5}$	$-1.16 \times 10^{-3}$ , $1.20 \times 10^{-3}$	$9.72 \times 10^{-1}$
<b>Multivariable Adjusted Model<sup>a</sup></b>			
<b>Percent Change in Omega 6 PUFA from 1990 to 2010</b>	$3.75 \times 10^{-02}$	$1.64 \times 10^{-02}$ , $5.86 \times 10^{-02}$	$6.50 \times 10^{-04}$


468 <sup>a</sup> Adjusted for: Percent Change in Long Chain Omega3 PUFA, Percent Change in Saturated Fat, Percent Change  
 469 in Trans-fat, and Percent Change in Dietary Cholesterol, and change in Gross National Income level. To  
 470 account for distinct associations on opposite sides of the threshold for saturated fat, the saturated fat variable  
 471 was interacted with a dichotomous dummy variable for *change-occurred-above-or-below threshold*. Trans-fat  
 472 and dietary cholesterol also had thresholds and were modeled in the same way.

473

474 **Figure 1. Free-knot penalized splines showing the relationship between country-level lipid intakes and age standardized**  
475 **incidence of Alzheimer Disease and other dementias**

476 Incidence is on the y-axis and the y axis range is the same for all 5 plots, for ease of comparison. Each plot depicts the penalized  
477 regression spline for a distinct class of country-level lipid data: (A) Omega6 PUFA (B) Long Chain Omega3 PUFA (C) Saturated Fat  
478 (D) Trans-fat and (E) Dietary Cholesterol intake. The dashed lines depict 95% CIs and the hash marks along the x-axis depict data  
479 density. Estimates are imprecise in regions of low data density. Nonlinear relationships were detected by the GCV process for  
480 Saturated Fat, Trans-fat, Dietary Cholesterol (panels C-E). Apparent thresholds are indicated with a vertical red line.

481



482

483

484

## Research in Context

Evidence before this study: Convergent evidence from genetics, neuropathology, laboratory experiments, and epidemiology indicates that lipids play a central role in the development of Alzheimer Disease (AD). However, the relative importance of different lipids remains unclear, and individual-level epidemiologic studies are often not well suited to address this question. Large cohort studies rarely have precise dietary information on specific lipid intakes over decades, and even where these data are available, the lipid intakes among individuals do not typically vary enough within a study population to discern patterns of association. Additionally, multiple categories of lipids are not usually available in one dataset, so their relative associations cannot be compared. Lastly, the potential for nonlinear relationships is rarely considered. These caveats often lead to equivocal conclusions upon meta-analysis. However, each of these issues is addressable with analyses on the country-level.

Added value of this study: Here we obtained country-level data on five lipid intakes, and compared them to age-standardized Alzheimer Disease Incidence rates (ASAIR) using free-knot penalized spline regression and linear regression. We found that Omega6 Polyunsaturated-Fatty-Acid (PUFA) intake exhibited a linear and significant relationship with ASAIR and it was validated in a follow-up longitudinal analysis. Additionally, we found non-linear relationships between saturated-fat, trans-fat, dietary-cholesterol and ASAIR. For each of these, ASAIR increased with lipid intake up to a threshold although these relationships were not statistically significant in the longitudinal analysis.

Implications of all the available evidence: When combined with the pre-existing evidence, these analyses indicate that decreasing Omega6-PUFA consumption on the country-level may have substantial benefits in reducing AD rates. Further research is needed on all these lipids, but country level reductions in saturated-fat, trans-fat, dietary-cholesterol intake, hold similar promise for reducing the country level burden of dementia. When considered in aggregate, reductions in the mean intake of four lipids may yield significant reductions in AD incidence. Individual level studies must be conducted to determine the impact of lipid intakes on specific people.

## Highlights

Diverse convergent evidence indicates that lipids play a role in Alzheimer Disease.

Individual-level studies are often not well suited to study lipid consumption.

Incidence of Alzheimer Disease and other dementias increased with mean country-level Omega6 PUFA intake

It also increased with saturated-fat, trans-fat, and cholesterol up to a threshold.

The country-level Omega6 PUFA finding was validated in longitudinal analyses.